Last reviewed · How we verify
ALVAC(2)120(B,MN)GNP (vCP1452)
ALVAC(2)120(B,MN)GNP is a recombinant canarypox virus-based vaccine that expresses HIV-1 gp120 and other viral antigens to elicit cellular and humoral immune responses against HIV-1.
ALVAC(2)120(B,MN)GNP is a recombinant canarypox virus-based vaccine that expresses HIV-1 gp120 and other viral antigens to elicit cellular and humoral immune responses against HIV-1. Used for HIV-1 prevention (therapeutic vaccine candidate).
At a glance
| Generic name | ALVAC(2)120(B,MN)GNP (vCP1452) |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | Viral vector vaccine |
| Target | HIV-1 gp120 envelope glycoprotein |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This vaccine uses a live attenuated canarypox virus vector to deliver HIV-1 envelope glycoprotein (gp120) and other immunogenic sequences from HIV-1 clades B and MN. The vaccine is designed to stimulate both CD8+ T-cell and antibody responses to prevent or control HIV-1 infection. It was developed as part of the HVTN 702 trial and subsequent HIV vaccine development programs.
Approved indications
- HIV-1 prevention (therapeutic vaccine candidate)
Common side effects
- Injection site reactions (pain, erythema, induration)
- Fever
- Myalgia
- Fatigue
Key clinical trials
- Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults (PHASE1)
- Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination (PHASE3)
- Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination (PHASE2)
- Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV (PHASE1, PHASE2)
- Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452 (PHASE1)
- Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC (PHASE1)
- A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers (PHASE1)
- Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: